Authors

• Brian Doyon
• Madhavi Bandi (ORCID: https://orcid.org/0000-0002-7562-0170)
• Tianshu Feng (ORCID: https://orcid.org/0000-0002-9445-4876)
• William D. Mallender
• Robert Tjin Tham Sjin (ORCID: https://orcid.org/0000-0002-3809-8424)
• Jannik N. Andersen (ORCID: https://orcid.org/0000-0003-4528-2120)
• Erik Wilker (ORCID: https://orcid.org/0000-0003-4535-178X)
• Douglas A. Whittington (ORCID: https://orcid.org/0000-0002-5946-8543)
• Alan Huang (ORCID: https://orcid.org/0000-0001-5501-0212)
• Yi Yu (ORCID: https://orcid.org/0000-0002-2223-337X)
• Xuewen Pan (ORCID: https://orcid.org/0000-0002-0148-5631)
• Katherine Lazarides (ORCID: https://orcid.org/0000-0002-0878-0465)
• Shangtao Liu (ORCID: https://orcid.org/0000-0002-2724-9178)
• Hongxiang Zhang (ORCID: https://orcid.org/0000-0001-6794-0038)
• Ashley H. Choi (ORCID: https://orcid.org/0000-0002-2802-7163)
• Justin L. Engel (ORCID: https://orcid.org/0000-0002-2016-3494)
• Binzhang Shen (ORCID: https://orcid.org/0000-0002-6556-7791)
• Samuel R. Meier (ORCID: https://orcid.org/0000-0002-7026-2722)
• Brian J. McMillan (ORCID: https://orcid.org/0000-0002-3134-7774)
• Michele Meseonznik

Publication Details

Published

2025-09-02

DOI

https://doi.org/10.1158/1535-7163.30028919

Primary Topic

PARP inhibition in cancer therapy

Type

article

Field-Weighted Citation Impact

0.00